MEDNAX

Pediatrix Medical Group, Inc. engages in the provision of physician services. It includes newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care. The company was founded by Roger J. Medel in 1979 and is headquartered in Sunrise, FL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

MEDNAX reports stable Q4 performance, eyes in-network growth opportunities

MEDNAX's Q4 call highlighted stable performance, strategic focus on core areas, and challenges from R1 transition and labor inflation. Opportunities in payer relationships, acquisitions, and organic growth are key for future success.

MEDNAX (MD) reports solid Q1 performance, eyes growth opportunities

MEDNAX's Q1 2023 performance showcased stability in patient volumes, pricing strength, and effective cost management. The company's focus on revenue cycle management and debt reduction yielded positive outcomes. Addressing challenges and seizing growth opportunities will be key for sustained success.

MEDNAX (MD) reports strong Q2 performance and eyes growth opportunities

MEDNAX (MD) delivers a solid performance in Q2 2023 with stable patient volumes, strong pricing, and cost efficiencies. The company's focus on improving AR collections, expanding clinics, and potential acquisitions positions it well for future growth.

MEDNAX reports Q3 earnings below forecast, revises full-year outlook

MEDNAX acknowledges disappointing Q3 results, plans structural changes to address challenges, and revises full-year adjusted EBITDA outlook. Despite facing operational challenges, the company shows strength in managing cash and negotiating subsidies with hospital partners.

MEDNAX meets Q4 expectations, eyes stable growth and cost efficiencies

MEDNAX's Q4 performance met expectations, with a focus on stabilizing margins and narrowing financial performance range. The company is poised for stable revenue growth in 2024, with opportunities to deploy capital for acquisitions and improve cost efficiencies. Challenges include stabilizing margins and addressing modest revenue growth expectations.

MEDNAX reports strong Q1 results, accelerates restructuring for growth

MEDNAX's Q1 performance reflects positive revenue growth and operational efficiency initiatives. While facing challenges in communicating practice exits and financial impacts, the company is well-positioned to capitalize on growth opportunities in core services. By focusing on restructuring and maintaining financial discipline, MEDNAX aims to drive continued progress throughout 2024.

MEDNAX surpasses Q2 expectations, focuses on strategic realignment for growth

MEDNAX's Q2 performance exceeded expectations with revenue growth and cost efficiencies driving results.
While facing challenges from restructuring, the company aims to capitalize on opportunities for margin improvement.
Maintaining financial outlook, appointing new leadership, and strategic shifts position MEDNAX for future growth.
Overall, MEDNAX's focus on operational enhancements and strategic realignment bode well for its financial health.

MEDNAX surpasses Q3 expectations with strategic initiatives driving growth

MEDNAX delivered strong Q3 performance with revenue growth, stable patient volumes, and successful operational transitions.
Strategic initiatives like portfolio restructuring and improved liquidity position highlight the company's focus on long-term sustainability.
While challenges like executing restructuring plans and managing liquidity exist, opportunities for growth and value creation are also present.
Overall, MEDNAX's financial outlook remains positive, supported by operational efficiency and prudent financial management.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

The headline numbers for Pediatrix Medical Group (MD) give insight into how the company performed in the quarter ended June 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Pediatrix Medical Group (MD) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

Pediatrix (MD) reiterates adjusted EBITDA guidance in the range of $235-$245 million for 2023 compared with $241 million in 2022.

Pediatrix (MD) Q2 Earnings Meet Estimates, Revenues Up Y/Y

Pediatrix Medical Group (MD) came out with quarterly earnings of $0.39 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.47 per share a year ago.

Pediatrix Medical Group (MD) Meets Q2 Earnings Estimates

Progyny

Investors interested in stocks from the Medical Services sector have probably already heard of Pediatrix Medical Group (MD) and Progyny (PGNY). But which of these two stocks offers value investors a better bang for their buck right now?

MD vs. PGNY: Which Stock Is the Better Value Option?

FORT LAUDERDALE, Fla.--(BUSINESS WIRE)---- $MD--Pediatrix Medical Group 2023 Second Quarter Conference Call/Webcast Scheduled for Thursday, August 3, 2023.

Pediatrix Medical Group 2023 Second Quarter Conference Call/Webcast Scheduled for Thursday, August 3, 2023

Pediatrix Medical Group (MD) reported earnings 30 days ago. What's next for the stock?

Why Is Pediatrix Medical Group (MD) Down 4.9% Since Last Earnings Report?

Investors are likely concerned about Pediatrix's (MD) lower enrollment in commercial insurance programs, escalating practice salaries and benefits and net borrowings.

Pediatrix (MD) Down 4.2% Despite Q1 Earnings & Revenue Beat

FORT LAUDERDALE, Fla.--(BUSINESS WIRE)---- $MD--Pediatrix Board Appoints Sylvia Young as Independent Director.

Pediatrix Board Appoints Sylvia Young as Independent Director

FORT LAUDERDALE, Fla.--(BUSINESS WIRE)---- $MD--Pediatrix Medical Group to Present at 2023 Bank of America Health Care Conference.

Pediatrix Medical Group to Present at 2023 Bank of America Health Care Conference

Pediatrix Medical Group, Inc. (NYSE:MD ) Q1 2023 Earnings Conference Call May 2, 2023 9:00 AM ET Company Participants Charles Lynch - SVP, Finance and Strategy Jim Swift - CEO Marc Richards - CFO Conference Call Participants Kevin Fischbeck - Bank of America Taji Phillips - Jefferies Jack Senft - William Blair A.J. Rice - Credit Suisse Kieran Ryan - Deutsche Bank Whit Mayo - SVB Securities Operator Ladies and gentlemen, thank you for standing by.

Pediatrix Medical Group, Inc. (MD) Q1 2023 Earnings Call Transcript

Pediatrix Medical Group (MD) came out with quarterly earnings of $0.23 per share, beating the Zacks Consensus Estimate of $0.22 per share. This compares to earnings of $0.33 per share a year ago.

Pediatrix Medical Group (MD) Tops Q1 Earnings and Revenue Estimates

FORT LAUDERDALE, Fla.--(BUSINESS WIRE)---- $MD--Pediatrix Medical Group 2023 First Quarter Conference Call/Webcast Scheduled for Tuesday, May 2, 2023.

Pediatrix Medical Group 2023 First Quarter Conference Call/Webcast Scheduled for Tuesday, May 2, 2023

Pediatrix Medical Group (MD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Pediatrix Medical Group (MD) to Report a Decline in Earnings: What to Look Out for

FORT LAUDERDALE, Fla.--(BUSINESS WIRE)---- $MD--James D. Swift, M.D.

James D. Swift, M.D., Elected to Pediatrix Board of Directors

Pediatrix (MD) anticipates 2023 adjusted EBITDA to be within $235-$245 million.

Pediatrix (MD) Q4 Earnings miss on High Operating Expenses

Pediatrix Medical Group, Inc. (NYSE:MD ) Q4 2022 Earnings Conference Call February 17, 2023 9:00 AM ET Company Participants Charles Lynch – Senior Vice President, Finance and Strategy Mark Ordan – Executive Chair Jim Swift – Chief Executive Officer Marc Richards – Chief Financial Officer Conference Call Participants Jack Senft – William Blair AJ Rice – Credit Suisse Pito Chickering – Deutsche Bank Whit Mayo – SVB Securities Kevin Fischbeck – Bank of America Rishi Parekh – JPMorgan Tao Qiu – Stifel Brian Tanquilut – Jefferies Operator Ladies and gentlemen, thank you for standing by, and welcome to the Fourth Quarter 2022 Earnings Conference Call. At this time all participants are in a listen-only mode.

Pediatrix Medical Group, Inc. (MD) Q4 2022 Earnings Call Transcript

Pediatrix Medical Group (MD) delivered earnings and revenue surprises of -4.08% and 2.43%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Pediatrix Medical Group (MD) Lags Q4 Earnings Estimates

Pediatrix Medical's (MD) fourth-quarter results are likely to reflect higher operating expenses and patient volume growth.

Pediatrix Medical (MD) to Post Q4 Earnings: What to Expect

Earnings Preview: Pediatrix Medical Group (MD) Q4 Earnings Expected to Decline

FORT LAUDERDALE, Fla.--( BUSINESS WIRE )--Pediatrix Medical Group, Inc. (NYSE: MD) will host an investor conference call and webcast on Friday, February 17, 2023 at 9:00 a.m. ET to discuss results from operations for the quarter ended December 31, 2022. A detailed press release will be issued the morning of February 17, 2023 before the securities markets open.

Pediatrix Medical Group 2022 Fourth Quarter Conference Call/Webcast Scheduled for Friday, February 17, 2023

Fintel reports that Starboard Value LP has filed a 13D/A form with the SEC disclosing ownership of 3,348,578 shares of MEDNAX Inc (MD).

Starboard Value Cuts Stake in Mednax

FORT LAUDERDALE, Fla.--( BUSINESS WIRE )--Pediatrix Medical Group, Inc. (NYSE: MD), the nation's leading provider of highly specialized health care for women, babies and children, today announced that the Company's board of directors has appointed James D. Swift, M.D., as chief executive officer, to succeed Mark S. Ordan, who has been named executive chair of the Company's board of directors and has served as chief executive officer since July 2020. Guy P. Sansone, who previously served as chair of the Company's board of directors since July 2020, has been named lead independent director. Each of these transitions will go into effect at the end of the year.

Pediatrix Announces Leadership Transitions

FORT LAUDERDALE, Fla.--( BUSINESS WIRE )--Pediatrix® Medical Group, Inc. (NYSE: MD), the nation's leading provider of highly specialized health care for women, babies and children, today released its inaugural sustainability report which outlines Pediatrix's approach and business practices related to its Environmental, Social and Governance (ESG) efforts. The report is a milestone in the company's commitment to transparently providing ESG information to its key stakeholders.

Pediatrix® Medical Group Releases Inaugural Sustainability Report

Pediatrix's (MD) Q3 results reflect volume constraints and an elevated expense level. Adjusted EBITDA is now expected within $240-$245 million, down from the earlier view of $260-$270 million.

News for MEDNAX Stock (MD)